Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo) için istatistikler
Toplam ziyaret
| views | |
|---|---|
| Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo) | 0 |
Aylık toplam ziyaret
| views | |
|---|---|
| Ocak 2024 | 0 |
| Şubat 2024 | 0 |
| Mart 2024 | 0 |
| Nisan 2024 | 0 |
| Mayıs 2024 | 0 |
| Haziran 2024 | 0 |
| Temmuz 2024 | 0 |
